Solyanik O, Heimer M. [Clinical impact of abbreviated unenhanced prostate protocols in magnetic resonance imaging].
Radiologe 2021;
61:810-817. [PMID:
34297140 DOI:
10.1007/s00117-021-00890-8]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/28/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND
According to the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 multiparametric magnetic resonance imaging (mpMRI) with gadolinium-(Gd)-based contrast agents is the diagnostic standard of care in the detection of prostate cancer (PCa). Recent data suggest equivalent performance of biparametric MRI (bpMRI) and mpMRI in defined indications.
OBJECTIVES
Evaluation of the current role of abbreviated or unenhanced protocols in MRI of the prostate in various clinical settings.
MATERIALS AND METHODS
Evaluation of clinical trials, guidelines and expert opinions.
RESULTS
The use of dynamic contrast-enhanced (DCE) MRI sequences is associated with contrast agent-associated risks and has significant impact on the imaging procedure and costs. Arguments for and against the use of contrast agent in prostate protocols as well as equivalence from bpMRI and mpMRI are discussed.
CONCLUSIONS
Currently, bpMRI can only be performed if very good image quality is available and in the hands of a radiologist with extensive experience in reading prostate MRI. There is a need for prospective studies to qualify bpMRI as the diagnostic method for the primary diagnosis of PCa.
Collapse